Table 2.
Characteristics of studies included in meta-analysis.
| References | Country | Follow-up duration (months) | Inclusion of participants with history of surgery | Surgical interventions (study arm) | Number of eyes (participants) randomized | Baseline mean age (months) | Baseline mean IOP (mmHg) | Postoperative 6-month mean IOP reduction (mmHg) | Postoperative 1-year mean IOP reduction (mmHg) | Surgical success rate (%) a |
|---|---|---|---|---|---|---|---|---|---|---|
| Elwehidy et al. 9 | Egypt | 36 | No | VCST | 84 (49) | 4.8 (2.1) | 29.1 (3.3) | 17.9 (3.0) | 17.7 (3.0) | 94.6 |
| CPT+VC | 4.9 (1.7) | 29.9 (3.2) | 18.0 (2.8) | 17.1 (2.8) | 87.8 | |||||
| Elhilali et al. 10 | Egypt | 12 | No | KDB trabeculectomy | 42 (29) | 9.1 (9.6) | 24.4 (6.8) | 10.1 (6.0) | 12.6 (6.0) | 57.1 b |
| Goniotomy | 6.3 (3.9) | 23.1 (3.7) | 9.9 (3.3) | 10.3 (3.3) | 57.1 b | |||||
| Elwehidy et al. 11 | Egypt | 60 | No | CPT+VC | 154 (92) | 5.0 (2.3) | 26.5 (2.9) | 15.0 (2.5) | 14.4 (2.5) | 89.7 |
| CPT | 5.0 (2.9) | 27.9 (3.1) | 16.2 (2.7) | 15.2 (2.7) | 85.5 | |||||
| Bor’i et al. 12 | Egypt | 14 (13–22) c | No | TmS | 50 (25) | 2.5 (0.5) | 31.6 (4.9) | 18.6 (4.3) | 16.1 (4.3) | 84.0 |
| TM | 2.5 (0.5) | 32.1 (4.0) | 17.1 (3.5) | 15.0 (3.6) | 88.0 | |||||
| Wagdy13 | Egypt | 12 | Yes | 240° trabeculotomy | 30 (30) | 14.1 (2.3) | 28.2 (1.7) | 14.0 (1.9) | 14.3 (1.8) | 93.3 d |
| CTTM | 14.2 (3.1) | 28.1 (3.5) | 13.5 (3.1) | 13.5 (3.1) | 86.7 d | |||||
| Rolim-de-Moura et al. 14 | Brazil | 12 | Yes | Baerveldt implant | 13 (13) | 40.8 (31.7) | 22.8 (5.9) | 10.6 (6.4) | 10.6 (5.2) | 100.0 |
| CTTM | 28.6 (17.7) | 23.7 (7.3) | 8.6 (8.0) | 8.1 (6.7) | 100.0 | |||||
| El Sayed et al. 15 | Egypt | 24 | No | IMCT | 62 (62) | 5.6 (4.8) | 25.1 (6.4) | 13.3 (5.7) | 13.2 (5.5) | 89.3 |
| CPT | 4.4 (3.8) | 22.3 (5.2) | 7.9 (5.1) | 9.5 (4.8) | 56.3 | |||||
| Shakrawal et al. 16 | India | 12 | No | IMCT | 40 (31) | 6.5 (3.9) | 24.7 (3.9) | 14.7 (3.5) | 15.2 (3.4) | 90.0 |
| CPT | 10.2 (5.4) | 24.6 (3.3) | 12.2 (2.9) | 12.9 (2.9) | 70.0 | |||||
| Khalil et al. 17 | Egypt | 36 | No | CPT | 28 (28) | 6.5 (3.9) | 24.1 (1.9) | 12.7 (4.2) | 14.1 (1.8) | 85.7 d |
| CTTM | 5.6 (4.0) | 24.1 (1.8) | 11.6 (4.5) | 13.6 (1.8) | 85.7 d | |||||
| Temkar et al. 18 | India | 12 | No | IMCT | 60 (30) | 6.6 (5.7) | 21.8 (9.8) | 10.4 (8.9) | 10.2 (8.6) | 93.3 |
| CTTM | 6.6 (5.7) | 21.7 (8.9) | 10.7 (8.0) | 10.1 (7.8) | 93.3 | |||||
| ElSheikha et al. 19 | Egypt | 6 | Yes | CPT+VC | 41 (31) | 6.8 (6.5) | 23.5 (5.4) | 6.1 (6.4) | NA | 66.7 |
| CPT | 6.9 (5.7) | 24.3 (4.4) | 6.4 (6.4) | NA | 60.0 | |||||
| Bayoumi20 | Egypt | 12 | No | CTTM | 20 (20) | 4.7 (2.0) | 16.7 (4.3) | 10.9 (4.0) | 11.8 (3.7) | 100 b |
| CTTM+DS | 7.0 (3.8) | 16.4 (8.4) | 10.9 (7.4) | 10.8 (7.3) | 100 b | |||||
| Reddy et al. 21 | India | 6 | No | CTTM | 32 (18) | <24.0 | 24.9 (6.8) | 9.0 (5.9) | NA | 75.0 |
| TM | <24.0 | 27.3 (4.6) | 12.3 (5.0) | NA | 81.3 | |||||
| Noureddin et al. 22 | Lebanon | 12 | No | CPT | 16 (8) | 3.4 (4.1) | 34 (2.6) | 20.5 (4.2) | 18.4 (3.8) e | NA |
| VC | 3.4 (4.1) | 32.3 (4.1) | 17.2 (5.8) | 19.4 (4.0) e | NA | |||||
| Senft et al. 23 | Saudi Arabia | 9.5 (2-15) c | Yes | Goniotomy | 20 (10) | 5.7 (3.9) | 28.4 (4.6) | 4.8 (7.8) f | NA | 40.0b |
| Laser goniotomy | 5.7 (3.9) | 29.5 (11.0) | 6.4 (10.1) f | NA | 40.0 b | |||||
| Anderson24 | USA | 34 | No | Goniotomy | 18 (9) | <9.0 | NA | NA g | NA | 66.6 b |
| CPT | <9.0 | NA | NA g | NA | 66.6 b |
Data on age, IOP, and surgical success rate were rounded to one decimal place, if applicable.
CPT, conventional partial trabeculotomy; CTTM, combined trabeculectomy-trabeculotomy with mitomycin C; DS, deep sclerectomy; IMCT, illuminated microcatheter-assisted circumferential trabeculotomy; IOP, intraocular pressure; KDB, Kahook dual blade; NA, not available; TM, trabeculectomy with mitomycin C; TmS, trabeculectomy with modified scleral bed; VC, viscocanalostomy; VCST, visco-circumferential-suture-trabeculotomy.
Adopted data for the closest point in time to postoperative 6 months in cases where their data are not available.
No distinction between complete (absolute) and qualified success.
Average follow-up duration (range).
Complete (absolute) surgical success rate.
Adopted postoperative 16-month IOP data due to lack of 1-year data.
Adopted IOP data following surgical intervention (measurement period not specified).
Adopted average IOP value for all of the other included CPT studies’ postoperative 6-month data due to lack of data (applied identical values for both interventions, considering their identical surgical success rates).